Vistagen Therapeutics, Inc. Share-based Payment Arrangement, Expense in USD from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vistagen Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to Q3 2025.
  • Vistagen Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $1.1M, a 1.44% decline year-over-year.
  • Vistagen Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $4.06M, a 22.8% increase year-over-year.
  • Vistagen Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $4.32M, a 97.8% increase from 2023.
  • Vistagen Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.18M, a 34.6% decline from 2022.
  • Vistagen Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.34M, a 4.13% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Vistagen Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $4.06M $1.1M -$16K -1.44% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 $4.07M $916K -$244K -21% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $4.32M $963K +$441K +84.5% Jan 1, 2025 Mar 31, 2025 10-K 2025-06-17
Q4 2024 $3.87M $1.08M +$573K +113% Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-13
Q3 2024 $3.3M $1.11M +$528K +90.4% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 $2.77M $1.16M +$591K +104% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $2.18M $522K -$80K -13.3% Jan 1, 2024 Mar 31, 2024 10-K 2025-06-17
Q4 2023 $2.26M $507K -$239K -32.1% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-13
Q3 2023 $2.5M $584K -$448K -43.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $2.95M $569K -$388K -40.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $3.34M $602K -$800K -57.1% Jan 1, 2023 Mar 31, 2023 10-K 2024-06-11
Q4 2022 $4.14M $746K +$22.5K +3.11% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-13
Q3 2022 $4.11M $1.03M +$267K +35% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $3.85M $957K +$367K +62.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $3.48M $1.4M +$912K +186% Jan 1, 2022 Mar 31, 2022 10-K 2023-06-28
Q4 2021 $2.57M $724K -$6.6K -0.9% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-07
Q3 2021 $2.58M $765K +$354K +86.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $2.22M $590K -$84.2K -12.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $2.31M $490K Jan 1, 2021 Mar 31, 2021 10-K 2022-06-23
Q4 2020 $730K Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-10
Q3 2020 $411K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $675K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12

Vistagen Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $4.32M +$2.13M +97.8% Apr 1, 2024 Mar 31, 2025 10-K 2025-06-17
2023 $2.18M -$1.16M -34.6% Apr 1, 2023 Mar 31, 2024 10-K 2025-06-17
2022 $3.34M -$144K -4.13% Apr 1, 2022 Mar 31, 2023 10-K 2024-06-11
2021 $3.48M +$1.17M +50.9% Apr 1, 2021 Mar 31, 2022 10-K 2023-06-28
2020 $2.31M -$1.51M -39.6% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-23
2019 $3.82M +$377K +11% Apr 1, 2019 Mar 31, 2020 10-K 2021-06-29
2018 $3.44M +$1.1M +46.9% Apr 1, 2018 Mar 31, 2019 10-K 2020-06-29
2017 $2.34M +$1.49M +175% Apr 1, 2017 Mar 31, 2018 10-K 2019-06-25
2016 $851K -$3.19M -78.9% Apr 1, 2016 Mar 31, 2017 10-K 2018-06-26
2015 $4.04M +$1.58M +64.3% Apr 1, 2015 Mar 31, 2016 10-K 2017-06-29
2014 $2.46M Apr 1, 2014 Mar 31, 2015 10-K 2016-06-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.